Soaring 129% of the anti-tumor injection Hausen will win

Medical Network News on August 17 Recently, Hausen’s application for the imitation of azacitidine for injection in the category 4 listing has entered the "under review" status, and if it is successfully approved, it will become the fourth domestic company
.
This variety was included in the third batch of national sourcing.
Huiyu and Zhengda Tianqing successfully won the bid, and Xinji 2020's market share fell to 73.
05%
.
Figure 1: Hausen’s registration progress for azacitidine for injection.
Source: NMPA official website.
Azacitidine for injection is a nucleoside metabolism inhibitor that can be used to treat intermediate-risk-2/high-risk myelodysplastic syndromes (MDS) , Acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) with 20-30% bone marrow blasts
.
Figure 2: Sales of azacitidine for injection (unit: 10,000 yuan) Source: Meinenet.
com China's public medical institutions terminal competition pattern.
The original research drug was developed by the United States Xinji Company.
It was approved for listing in China in 2017 and negotiated in 2018.
Entering the national medical insurance catalogue, in 2019, Huiyu and Chia Tai Tianqing won approvals for domestic imitations (and deemed to have been reviewed).
With the joint efforts of “original research + imitations”, the product has been used in public hospitals in cities , county-level public hospitals, and public hospitals in China .
The terminal of urban community centers and township health centers (Chinese public medical institutions) ushered in a surge in sales, with a growth rate of 1232% that year
.
Figure 3: The medical insurance status of azacitidine for injection.
Source: Meinenet.
cn China Medical Insurance Catalogue Database The implementation of the quarter began, Huiyu and CP Tianqing successfully won the bid, and Xinji's market share is expected to be robbed
.
In 2020, in China's public medical institutions, the sales of this product has exceeded 200 million yuan, with a growth rate of 129%.
Xinji accounted for 73.
05% of the market, Zhengda Tianqing and Huiyu accounted for 20.
99% and 5.
97% respectively
.

　　Source: NMPA official website, Minet.
com database.
The review data statistics are as of August 13.
If there are any errors or omissions, please correct me
.